TOPICAL FORMULATION AND USE OF BUSPIRONE - ARACHNOVA THERAPEUTICS LTD

Title:

TOPICAL FORMULATION AND USE OF BUSPIRONE

Document Type and Number:

WIPO Patent Application WO2004084900

Kind Code:

A8

Abstract:

A liquid or semi-solid topical formulation of buspirone, when applied to human epidermis in vitro (following methods defined herein), results in a transepidermal flux rate of buspirone (individual or mean data) in one or more of the following ranges: 0.1 to 1.1 µg/cm<2>/hour as assessed over 5 hours following application; 0.09 to 0.60 µg/cm<2>/hour as assessed over 13 hours following application; 0.09 to 0.48 µg/cm<2>/hour as assessed over 24 hours following application; 0.08 to 0.46 µg/cm<2>/hour as assessed over 30 hours following application; and 0.08 to 0.39 µg/cm<2>/hour as assessed over 48 hours following application. Buspirone is useful for the manufacture of a topical medicament for use in the treatment of pruritus or an immune-related skin disease.

More Like This:

WO/2023/062353	NANOPARTICULATE FORMULATION
WO/2018/147620	PHARMACEUTICAL COMPOSITION FOR TREATING LUNG FIBROSIS, COMPRISING APOPTOTIC CELL AND STATIN-SERIES COMPOUNDS
JP6139781	The medicine delivery catalyst containing the substance which activates a Lylylin lipid receptor

Inventors:

CAVALLA DAVID (GB)
GRISTWOOD ROBERT WILLIAM (GB)

Application Number:

PCT/GB2004/001242

Publication Date:

December 09, 2004

Filing Date:

March 22, 2004

Export Citation:

Click for automatic bibliography generation Help

Assignee:

ARACHNOVA THERAPEUTICS LTD
CAVALLA DAVID (GB)
GRISTWOOD ROBERT WILLIAM (GB)

International Classes:

A61K9/00; A61K31/506; A61K47/00; A61P17/00; A61P17/04; A61P17/06; (IPC1-7): A61K31/505; A61P17/00; A61P17/04; A61P17/06

Download PDF:

View/Download PDF PDF Help

Previous Patent: MEDICINAL COMPOSITION CONTAINING PYRROLOPYRIDAZINE COMPOUND

Next Patent: USE OF A TRIOXOPYRIMIDINE FOR THE TREATMENT OF CHRONIC WOUNDS